docetaxel anhydrous has been researched along with Anal Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Almotlak, H; André, T; Baba-Hamed, N; Borg, C; Bouché, O; Buecher, B; de la Fouchardiere, C; Desrame, J; El Hajbi, F; Ghiringhelli, F; Jacquin, M; Jary, M; Kaminsky, MC; Kim, S; Meurisse, A; Nguyen, T; Parzy, A; Pernot, S; Saint, A; Samalin, E; Smith, D; Stouvenot, M; Taieb, J; Vernerey, D; Vienot, A; Zoubir, M | 1 |
| Cai, P; Chen, B; Gao, Y; Liao, Z; Wang, F; Wang, S; Xiao, W; Yuan, Y; Zeng, Z; Zhang, R | 1 |
| Lohynská, R; Pechačová, Z | 1 |
| André, T; Baba-Hamed, N; Bidard, FC; Borg, C; Bouché, O; Buecher, B; Dahan, L; de la Fouchardière, C; Desramé, J; El Hajbi, F; François, É; Ghiringhelli, F; Jacquin, M; Jary, M; Kim, S; Parzy, A; Rebucci-Peixoto, M; Samalin, E; Smith, D; Spehner, L; Taieb, J; Tougeron, D; Vendrely, V; Vernerey, D | 1 |
| Abdeljaoued, S; Adotevi, O; Borg, C; Buecher, B; François, E; Kim, S; Meurisse, A; Spehner, L; Vernerey, D; Vienot, A | 1 |
| Abdelghani, MB; André, T; Aparicio, T; Baba-Hamed, N; Bachet, JB; Bennouna, J; Bidard, FC; Bonnetain, F; Borg, C; Bouché, O; Buecher, B; De La Fouchardière, C; Desrame, J; Dumont, S; El Hajbi, F; François, E; Gornet, JM; Jacquin, M; Jary, M; Kim, S; Louvet, C; Nguyen, T; Parzy, A; Peiffert, D; Pernot, S; Samalin, E; Smith, D; Vendrely, V; Zoubir, M | 1 |
| Sclafani, F | 1 |
| Benzidane, B; Bonnetain, F; Borg, C; Bosset, JF; Cazorla, A; Delabrousse, E; Demarchi, M; Jary, M; Kaliski, A; Kim, S; Letondal, P; Mansi, L; Nguyen, T; Valmary-Degano, S | 1 |
| Fujita, T; Hori, S; Indo, S; Maeba, T; Mori, S; Takeuchi, H | 1 |
3 trial(s) available for docetaxel anhydrous and Anal Cancer
| Article | Year |
|---|---|
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2020 |
Anti-Telomerase CD4
Topics: Adaptive Immunity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Papillomavirus Infections; Prognosis; Prospective Studies; Telomerase; Th1 Cells | 2020 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; France; Humans; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Research Design; Taxoids; Young Adult | 2017 |
6 other study(ies) available for docetaxel anhydrous and Anal Cancer
| Article | Year |
|---|---|
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Paclitaxel; Prospective Studies | 2022 |
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
Topics: Adult; Aged; Anal Canal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Dermatitis; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Programmed Cell Death 1 Receptor; Radioimmunotherapy; Treatment Outcome | 2021 |
New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Humans; Immunotherapy; Neoplasm Recurrence, Local; Palliative Care | 2022 |
Building evidence-based treatment recommendations for advanced anal cancer: the time is now.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2018 |
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Human papillomavirus 16; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Squamous Cell; Papillomavirus Infections; Prospective Studies; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
[A case of effective chemoradiotherapy using docetaxel and nedaplatin for recurrent anal canal squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Female; Humans; Organoplatinum Compounds; Recurrence; Taxoids | 2013 |